Copyright
©The Author(s) 2022.
World J Clin Oncol. Jul 24, 2022; 13(7): 553-566
Published online Jul 24, 2022. doi: 10.5306/wjco.v13.i7.553
Published online Jul 24, 2022. doi: 10.5306/wjco.v13.i7.553
Table 1 Approved immune checkpoint inhibitors according to cancer type
| Anti-CTLA-4 antibodies |
| Ipilimumab; Colorectal cancer; Melanoma; Renal cell carcinoma |
| Anti-PD-1 antibodies |
| Nivolumab; Bladder cancer; Colorectal cancer; Head and neck cancer; Hepatocellular carcinoma; Hodgkin lymphoma; Melanoma; Non-small-cell lung cancer; Renal cell carcinoma; Cemiplimab; Cutaneous squamous cell carcinoma; Pembrolizumab; Bladder cancer; Cervical cancer; Gastro-oesophageal junction cancers; Head and neck cancer; Hepatocellular carcinoma; Hodgkin lymphoma; Merkel cell carcinoma; Metastatic solid tumours classified as microsatellite instability high or deficient mismatch repair; Non-small-cell lung cancer; Primary mediastinal large B cell lymphoma; Stomach cancer |
| Anti-PD-L1 antibodies |
| Atezolizumab; Bladder cancer; Breast cancer; Non-small-cell lung cancer; Avelumab; Bladder cancer; Merkel cell carcinoma; Durvalumab; Bladder cancer; Non-small-cell lung cancer |
- Citation: Nteli P, Bajwa DE, Politakis D, Michalopoulos C, Kefala-Narin A, Efstathopoulos EP, Gazouli M. Nanomedicine approaches for treatment of hematologic and oncologic malignancies. World J Clin Oncol 2022; 13(7): 553-566
- URL: https://www.wjgnet.com/2218-4333/full/v13/i7/553.htm
- DOI: https://dx.doi.org/10.5306/wjco.v13.i7.553